{"name":"Antengene Corporation","slug":"antengene-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPa3ZCSmdaNDdlS01pd1hVR3JiS041RFBCZ1QwMm5XXzVESnc1d1JNU1p3aVhSX0lpeE90SW9hcUNmN192Znp5UkJvN2kyWjA0aXdMUE10bV9ET3lHVUNNYUtiM05Ra2lXRE8tNjJFdnhXc3VqOTd5S2cxR01tSWowM0VENi1GeFBoeGxmOVRMaDBrUmhNbl9DVXl6UHVZdWhHeGRUMw?oc=5","date":"2026-03-04","type":"deal","source":"Pharmaceutical Executive","summary":"Antengene and UCB Enter $1.18 Billion Global License Agreement for Bispecific T-Cell Engager - Pharmaceutical Executive","headline":"Antengene and UCB Enter $1.18 Billion Global License Agreement for Bispecific T-Cell Engager","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNX0xCd0ttbDVLdm5FQXBPM2E1UDhzSm1BMTNuMXN0OUQ4bUd4M01GLUxqMFctdHVHeWNwQUoxS18ybG5EZF91V3JDbG00bjFsLW1ETjFVZDJWc09iOFFhaWR2QmdLZTZpeG1wTWhzd3JXVWJXYmtpWFM4U2ctbW9oMXd4QkRkYXVHX0lJQ0VrVTUzbnk2aGcyeWJoZ1RLRTQyM3VtRkMwUjV6U2s2VnBBMmdVTDVJX19kb1JmdDJrSS1NNWkxMGVrUU03eEl5MHc?oc=5","date":"2026-03-04","type":"deal","source":"European Pharmaceutical Review","summary":"UCB signs $1.1bn to autoimmune collaboration with Chinese biotech Antengene - European Pharmaceutical Review","headline":"UCB signs $1.1bn to autoimmune collaboration with Chinese biotech Antengene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5","date":"2026-03-04","type":"deal","source":"BioWorld News","summary":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE - BioWorld News","headline":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"pipeline","source":"South China Morning Post","summary":"China biotech outlicensing tops US$52 billion in first 2 months - South China Morning Post","headline":"China biotech outlicensing tops US$52 billion in first 2 months","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNM1QxOV9KUG9ocjNrdmRUeENSYjBKOFJNNUlUd0dEdy1HdkRycm80dS00X3Q5SDdDMXlGMXZwMlJlaHBJOUhldFJJd2ZaYnNsazhUQnlpZVFJVTZYQkxxNU9pX2ZaZlQ3QklvQ1NBZXpYcHM0SE1qNW1OWnlKSlFLTDN0UXZWdlpIWDdTOVd4UQ?oc=5","date":"2026-03-04","type":"deal","source":"The Pharma Letter","summary":"UCB inks license agreement with Antengene - The Pharma Letter","headline":"UCB inks license agreement with Antengene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPNF9YNzZfNFdvblZJeV9YWWViZVBLY1pxZlZ6LVZUVktXaGtwaXluejduNnVZNFhLay1lZmlXWnV3THJMNVMxNGpQczZnNTNhVEJlSk05dGxNeDlJV0VVR2l3bkVtZkFvZE5RLWE5VEQwMFBSSm5oeVcxMVBlTnVEMXZHTHRsX3ZfQkdMVkZEMXNxUi1CMm00bm5feER1aHZPXzZOeVY4cXpIeVZWR3cxUWtMQUpOWmpjNWZCdDJaUHdmYm1ROFZCQkcyNDA2WlY0bGN1R2hnOGNNQndvNzJQQmFBV2Nqb0RjOWYzbm1IWlVQRXdtV1JRQ1FGSXhwTnZXX0xTbi1jNA?oc=5","date":"2026-03-03","type":"deal","source":"prnewswire.com","summary":"Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases - prnewswire.com","headline":"Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPUFZXdG9JSzJjYjd6ZFIyeHJlMkVVQkp3VVRSalZ4YmNfdHNTSWRnX2tXclBhLWpFeUZJb3R4d2d1ZUdveTBqYkE2b2gxaGdtMEZOVGRyd29QN1VVblp2VHpMenQxdjdWdjI0Tjh1UWJpc29OYVlNRUJ3UlpqR0poTVJWbGZnZmFDUHRsUGhiUjZBZ2JTckxDV1ZPVUZpZGg3dEtBcnowa3Fzb211S3ZfeU43QWpTeFNpWWNVVg?oc=5","date":"2026-03-03","type":"deal","source":"Reuters","summary":"Belgium's UCB in autoimmune drug deal with Antengene - Reuters","headline":"Belgium's UCB in autoimmune drug deal with Antengene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNUzVnUUNqTVdBV0ZXaTg1eGx2b3FuZnZ3ZlR1VTFoMlM4OFF6aGdjLXBqaFJvRXBBN0N5ZXVUZzhpck11UExsWGI0WlJkWWVHQU1WN3U0WXpUclBrUHd5X3hXNGNBQlB6a0FBNnRmancydGpOTkVlcnRaV1VHNDVTTWUzUmx2eGhmTFF3TlMwM1kyZzRjemppcnZPZEdlN1puOVZRUjQ0bENjMUF6aDZSNVlLSkFlTXUtWFctTnljbkZ5ZDhPVHVtSXp5OA?oc=5","date":"2026-01-19","type":"trial","source":"BioPharma APAC","summary":"Antengene Showcases Next Phase Of Global Innovation At J P Morgan Healthcare Conference - BioPharma APAC","headline":"Antengene Showcases Next Phase Of Global Innovation At J P Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOTF9Hc18zTXFwanViT3BqYUNDTUlzVWtmSU4xVVpESExZWTQ4bldKZnNTQ2R0eWlGMTJ2cEs5TE1QZnFyNHR2MXBQdllRTXNrMnJMMlFkSlh2cG56R2R3WmNMaVMzRFFsYmpUeVZEVkQ5YUlIa1VmMzJMZFR4dVBYeEN1XzZYUkFOVlZvQWQyTUx2YzJZQnc0MVc0MnJDd3NYWl9NSQ?oc=5","date":"2025-05-21","type":"deal","source":"Contract Pharma","summary":"Antengene & MSD Enter into a Global Clinical Collaboration - Contract Pharma","headline":"Antengene & MSD Enter into a Global Clinical Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPVk5DSjdXTGhMelpJZ09wejJVemhyRGh5U2ZzTFVOb0J4dGlCZjV6WlI1U2czS21RTjJsR1I3WFI1MzhUNjZYYzNMQ0JJeVpPR2UtQmpYSWl6Xzg3dlpVVnQ0S0pfaEp3Vy01eXpOZENfMXBia3Q1b0pqdzlJQWg0dERIN0haajZYSndKNFJRWWpTQ2UxX0dxTGNlQjdjUzZkaV9qenpLX2JtUWdXRk1acEVGMWZQWlc2SGdKLUp6dzJ0dS1xNnN0ZmE4UmFsSjhRTHJCcEMxaEg5U1VjNjBFRjlIQU5WSnc?oc=5","date":"2025-05-21","type":"deal","source":"BioPharma APAC","summary":"Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors - BioPharma APAC","headline":"Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOVDdWa2VTajBPcmdTTWx0ODFZcllWZ3BUbUhiQzdWWnlKbmplMTdsNGpVVEVpazhIeXJaYU5lRnd5UXBiRzhDRE1WWjZNQ08tMWprQ3EtTmxMN3RIcXUxRFlITWpvaFlLb1VrMHRNR2RnNnBCSGdfTFNvbHc3ZmdsVFJXaUpCNkZ3ejNxQU1PQWxpdjJudllSZTlqVVhnczZYdVpXZ01YOXVPQ0lSSXdMNlFTUlJoRVExMXNERkFYalhaWDBvSURKQUFlVHVTQ01na05oOC1ZZ29TcW9PR19TTmcxS2dfc1VFaVBuS1R0ODZ2VXB3WUtYcEtXZzhya3NuU0NsZ0QtMl9wZ3QtUHJ2blFraEN5SDFhMXllOC1LWVVidUEwTkNWNHZ1RGI4dw?oc=5","date":"2023-08-10","type":"deal","source":"prnewswire.com","summary":"Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China - prnewswire.com","headline":"Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(se","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxPVGxnM2gwYTZ5bHNMajd5QkZyNTRtTVg1NWJUVktwbHhjOGlfbUU3WmNEUG9mclJCaDRCTGs0STZOWHZWNk9xWGRBaUJlY3FiRjY1VVREYjhvQWZZREJCWWJ3bkNtTWNLbl9HMExRWENqcVc1bDRaUk5Fa2VvV1RfWUJRbkhxN215RVc0MEdRUTVPRFdMMERIdGl5MjJGWEUtV1F5TldsY3JKNTNqbkxWZ1ZyRkZReVdGRG9lc3doSmNFcktWM1dBMW1oamUyUlJaNFNNd0pMc1lIcFNQTXhWSHc3ZFk3T0RTR0tobnQ3SUdibThWbk51WlF1ck05ZXBHTGtIT2ZZa2otcmR4RzRoMXYxTUtZdmxSellyYkJ2VFVKdUc0?oc=5","date":"2021-12-17","type":"regulatory","source":"Karyopharm","summary":"Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma - Karyopharm","headline":"Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Rel","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}